welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
Horizon Therapeutics plc today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in Atlanta. The U.S. Food and Drug Administration is currently evaluating under Priority Review a Biologics License Application (BLA) for teprotumumab in the treatment of active thyroid eye disease (TED). If approved, teprotumumab would be the first FDA-approved medicine for active TED. The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020. Teprotumumab is an investigational medicine and its safety and efficacy have not been established.
Oral Presentation: Teprotumumab, A Novel Biologic for Active Thyroid Eye Disease (abstract 1807)
Date: Monday, November 4, 2019
Time: 2:45-3:00 PM ET
The event has ended.
Gut Microbes May Play Role in Graves ’ Disease Diagnosis, Thyroid AutoimmunityThe abundance and diversity of intestina...
Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Di...Graves’ disease is an autoimmune condi...
Review of the Literature and Report of a Large Series of Patients Regarding the Association of Other Autoimmune Dise...Several studies have reported an associa...
Catherine J. Hwang, MDDr. Catherine J. Hwang was born in New Y...
Update on Graves’ Disease: Advances in Treatment of Mild, Moderate and Severe Thyroid Eye DiseasePurpose of Review: To report the most r...
“TED Today” Episode 4https://www.facebook.com/ThyroidEyes/vid...
Mayo ClinicMayo Clinic has a specialized endocrinol...